Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on July 27, 2011, to announce its financial and operating results for the quarter ended June 30, 2011. The key details of these results were provided in a press release, which was furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for the specific financial metrics, revenue figures, earnings per share, and operational highlights for the second quarter of 2011. While the 8-K itself does not contain the detailed financial data, it serves as the official notification that Regeneron has disclosed its performance. The press release, as referenced in the filing, is the primary source for understanding the company's financial health and operational progress during the reporting period. Investors interested in REGN's performance will need to review the accompanying press release for a comprehensive understanding of the quarter's outcomes.
Key Highlights
- 1Regeneron Pharmaceuticals (REGN) released its Q2 2011 financial and operating results on July 28, 2011.
- 2The results were announced via a press release, filed as Exhibit 99.1 with the SEC.
- 3The 8-K filing serves as the formal announcement of the Q2 2011 earnings release.
- 4Investors are directed to the furnished press release for detailed financial and operational data.
- 5The filing pertains to the quarterly period ending June 30, 2011.